Friday, 16 October 2026European Markets

METABOLIC EXPLORER Stock Impressive Drop 16% So Far On Friday, Underperforms Market

Loading stream...

metabolic explorer, a biochemistry company listed on the cac 40 as metex.pa, observed a significant drop in its share value today. the company's shares plummeted by 16.61%, closing at eur0.97, which remarkably outperformed the general market trend. the cac 40 itself noted only a 0.57% decrease today, ending on eur7,422.88, a dip that can be traced back to a continued uptick from yesterday. this movement in metabolic explorer's stock performance might be an indication of possible bearish trading conditions looming in the future.

performance evaluation over the past year

this biochemistry firm, known for developing industrial fermentation processes as alternatives to petrochemical processes, has witnessed a sharp fall in its stock price from its 52-week high of eur3.05. by closing friday at eur1.17, the company's market presence has suffered a significant blow.

insights from financial indicators

looking at metabolic explorer's financial indicators, their journey appears to be an uphill struggle. over the last twelve months, its earnings per share (eps) was negative by eur-1.13. this financial data indicates a challenging fiscal climate implying no profit generation during this period.

a closer look at the return on equity

moreover, the firm's return on equity, a crucial measurement of shareholder success in terms of how efficiently their investments with the company have been, has fallen below 39.56%. this drop signals their struggles and inability to convert these investments into profits.

investment decisions regarding metabolic explorer

given this unfortunate track record, it is advisable for investors and potential shareholders to execute due diligence before making their investment decisions towards metabolic explorer.

more news about metabolic explorer (metex.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com